Skip to main content
Clinical Trials/NCT03586388
NCT03586388
Completed
Not Applicable

Pilot Study on the Efficacy and Safety of an Oral Desensitization Protocol at the Onset of Food Allergy

IRCCS Burlo Garofolo1 site in 1 country73 target enrollmentMarch 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypersensitivity, Milk
Sponsor
IRCCS Burlo Garofolo
Enrollment
73
Locations
1
Primary Endpoint
number of children that completed the home oral immunotherapy protocol, reaching clinical tolerance
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Cow's milk (CM) allergy is the most frequent food allergy in the first years of life, with prevalence rates estimated in the range of 2-3%.

The elimination of CM is the mainstay of treatment, but accidental exposure to CM proteins is not uncommon, with a considerable risk of severe allergic reactions.

Recent evidence suggests that early oral exposure in young children may protect to the development of allergy. On the same way, strategies have been developed for the use of oral exposure as immunotherapy for the treatment of children with established food allergy even if available data on the use of oral immunotherapy in infants with food allergy are very limited.

The aim of this study is to evaluate the feasibility of an oral immunotherapy protocol, started in the first year of life, in children with CM allergy.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
June 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
IRCCS Burlo Garofolo
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • children between 3-12 months with CM allergy (defined as the association of typical clinical manifestations in the first hour after CM ingestion and evidence of sensitization of CM proteins on both skin prick test and specific serum IgE levels)

Exclusion Criteria

  • children with not IgE-mediated clinical manifestations
  • children with a known immunodeficiency

Outcomes

Primary Outcomes

number of children that completed the home oral immunotherapy protocol, reaching clinical tolerance

Time Frame: 6 months

Clinical tolerance defined as the achievement of a dose of 150 ml of CM or a corresponding dose of dairy products

Secondary Outcomes

  • Clinical reactions experienced by children at home(6 months)
  • Serum levels of specific IgE(6 months)
  • Serum levels of specific IgG4(6 months)

Study Sites (1)

Loading locations...

Similar Trials